Funding Opportunities

We offer funding for Alzheimer's drug discovery and preclinical development, clinical trials, and biomarker development research. Visit our Research Priorities for specific information about our interests.

Our funding is open to:
• Researchers, clinicians, and postdoctoral fellows
• Working in academia and biotechnology companies
• Based in the U.S. and worldwide

The ADDF currently accepts grant proposals through the following RFPs. (For returning grantees, we accept proposals for follow-on funding and renewals.)

CORE REQUESTS FOR PROPOSALS

Preclinical Drug Discovery RFP

Purpose:

Seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to Alzheimer's disease, related dementias and cognitive aging.

Next Deadlines: (4/year)

Letter of Intent: November 18, 2016
Invited Full Proposal: December 9, 2016

Program to Accelerate Clinical Trials (PACT) RFP

Purpose:

Designed to increase the number of novel and repurposed treatments tested in humans for Alzheimer's disease, related dementias and cognitive aging. It funds biomarker-based, proof-of-concept pilot clinical trials for Alzheimer's, as well as Phase 1 safety testing and IND-enabling studies to accelerate new drugs into trials.

Next Deadlines: (4/year)

Letter of Intent: November 18, 2016
Invited Full Proposal: December 9, 2016